MBRX - Moleculin further collaborates to advance WP1122 in COVID-19

Moleculin Biotech (MBRX) inks agreement with the University of Campinas in São Paulo, Brazil to further enable collaboration into its research on the anti-viral capabilities of its drug candidate WP1122, specifically for the coronavirus. Recently the University of Campinas published independent research demonstrating that SARS-CoV-2 infection is supported by elevated glucose levels and that inhibition of glycolysis with 2-deoxy-D-glucose (2-DG) effectively eliminated viral load in vitro. WP1122 is a pro-drug of 2-DG. "Adding the University of Campinas to our current collaborations which include The Rega Institute in Belgium and our sponsored research, increases our available resources in developing WP1122," commented Wally Klemp, Chairman and CEO of Moleculin.Shares +2% premarket.

For further details see:

Moleculin further collaborates to advance WP1122 in COVID-19